Background: Regularly participate international High-level in sports athletes national and competitions and engage in intense training, developing endurance and resilience. Measuring blood lactate levels is crucial for improving an athlete’s performance, assessing sports performance, and enhancing the effectiveness of future training. Aim: To study the relationship between lactate levels in the blood plasma and lactate dehydrogenase enzyme activity in Mongolian National Team athletes. Materials and Methods: The study involved 51 athletes from the Mongolian National Team. Anaerobic capacity was assessed using a Monark 894E Ergomedic Peak Bike, designed to apply exercise load. Blood serum lactate level and lactate dehydrogenase enzyme activity were determined using a Biobase BK-280 fully automated biochemical analyzer. Heart rate, peripheral blood oxygen levels, and oxygen saturation were measured using a pulse oximeter. Results: The average age of the participants was 24.04 ± 4.15 years, with an average height of 168 ± 8.78 cm and an average weight of 71.01 ± 7.69 kg. The average BMI was 24.82 ± 4.12 kg/m². Pre exercise lactate levels averaged 3.84 ± 0.75 mmol/L, while post-exercise lactate levels averaged 9.67±3.52 mmol/L. The average heart rate before exercise was 66.04±8.9 bpm, while post-exercise heart rate was 123.6±16.06 bpm. The average VO₂ max was 95.18±2.48. Conclusion The lactate levels before and after exercise among the athletes participating in the study showed significant differences in the age groups 20-29 (p<0.0001). When comparing lactate levels before and after exercise by sport, statistically significant increases were observed in freestyle wrestling and judo athletes (p<0.0001)

BACKGROUND. To introduce a new electronic technology which is mobile-based ophthalmoscope to the clinical practice for the patients with diabetes and hypertension. MATERIAL AND METHODS. There are 32 participants who were diagnosed with hypertension (blood pressure measured more than 140/90 mm Hg three times a month or for 2 weeks) participated in our study. We selected the patients with type II diabetes and hypertension who were referred to the RTW diabetes center. RESULTS. In the hypertensive group, based on Keith Wagener Barker (KWB) Grades, there are 1st and 2nd degree retinopathy cases are more common and it increases with the age. In the diabetic group, non-proliferative diabetic retinopathy is diagnosed among the patients aged above 60 years old and it correlates with the duration of disease.

To evaluate the efficacy and safety of bevacizumab monotherapy or combined with laser versus laser monotherapy in Mongolian patients with visual impairment due to diabetic macular edema.Prospective, randomized, single-center, a 12 month, laser-controlled, clinical trial. Participants: One hundred twelve eligible patients, aged ≥18 years, with type 1 or 2 diabetes mellitus and best corrected visual acuity (BCVA) in the study eye of 35 to 69 Early Treatment Diabetic Retinopathy Study (ETDRS)letters at 4 m (Snellen equivalent: ≥6/60 or ≤6/12), with visual impairment due to center-involved diabetic macular edema (DME). Methods: Patients were randomized into three treatment groups:(I) intravitreal bevacizumab monotherapy (n=42), (II) intravitreal bevacizumab combined with laser (n=35), (III) laser monotherapy (n=35). Bevacizumab injections were given for 3 initial monthly doses and then pro re nata (PRN) thereafter based on BCVA stability and DME progression. The primary efficacy endpoints were the mean change in BCVA and central retinal subfield thickness (CRST) from baseline to month 12.Bevacizumab monotherapy or combined with laser were superior to laser monotherapy in improving mean change in BCVA letter score from baseline to month 12 (+8.3 and +11.3 vs +1.1 letters; both p<0.0001). There were significant difference detected between the bevacizumab and bevacizumab combined with laser treatment groups (p=0.004). At month 12, greater proportion of patients gained ≥10 and ≥15 letters and with BCVA letter score >73 (Snellen equivalent: >6/12) with bevacizumab monotherapy (23.8% and 7.1% and 4.8%, respectively) and bevacizumab + laser (57.1% and 28.6% and 14.3%, respectively) versus laser monotherapy. The mean central retinal subfield thickness was significantly reduced from baseline to month 12 with bevacizumab (−124.4 μm) and bevacizumab + laser (−129.0 μm) versus laser (−62.0 μm; both p<0.0001). Conjunctival hemorrhage was the most common ocular events. No endophthalmitis cases occurred.Bevacizumab monotherapy or combined with laser showed superior BCVA improvements over macular laser treatment alone in Mongolian patients with visual impairment due to diabetic macular edema.